QMS Medical Allied Services Ltd
QMS Medical Allied Services Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Product side growth expected around 10% to 12% annually, aligned with pharma industry growth (Page 12). Product segment expected to grow at 10-12% annually, aligned with pharma industry growth.
From QMS Medical Allied Services Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Product side growth expected around 10% to 12% annually, aligned with pharma industry growth (Page 12).
- Service sector anticipated to grow at a faster rate, potentially doubling the growth rate of products, around 20-25% (Page 13).
- Overall revenue growth driven significantly by patient service programs expansion and new service launches (Page 12).
- Increase in healthcare camps with approximately 33,000 camps expected annually, maintaining or slightly increasing volumes (Page 9).
- Expansion plans include widening market reach in India and pilot projects for Asia-Pacific expansion in 5-10 years (Page 10).
2 more points management made on revenue & sales performance
Profitability & Margins
See what QMS Medical Allied Services Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company is investing heavily in infrastructure and people to support growth and improve margins; these investments are expected to show results from next year onwards.
- Investments are being made in technology adoption, capability building, brand building, field force expansion, and operational discipline.
- Focus on integrating AI into analytics and CRM systems is underway, with plans to expand AI usage for treatment insights and market data analytics in the future.
- Increasing field force numbers to scale healthcare camps and expand service reach across geographies.
2 more points management made on capital expenditure plans
Top-ranked in Healthcare Equipment & Supplies
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what QMS Medical Allied Services Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The transcript does not explicitly mention a specific current or expected order book value or pending orders in monetary terms.
- However, the company reported steady revenue growth and continued strong operational execution with a high number of healthcare camps (around 16,000+ in the first half).
- Saarathi Healthcare acquisition numbers (26% stake acquisition) will be reflected next quarter, indicating upcoming revenue contributions.
- Discussions and pipelines are ongoing, for example, about 16 programs currently running under Saarathi, with more in the pipeline.
2 more points management made on order book & pipeline
QMS Medical Allied Services Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹37 Cr, net profit ₹3 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What QMS Medical's management said in earlier quarters
Others in Healthcare Equipment & Supplies this season
- Tarsons Products (Q2 FY26)
Plastic labware market is expanding faster than glass, currently at INR1,200 crores, signaling long-term sector growth opportunities. Key concall takeaways…
- Vaidya Sane Ayurved Laboratories Ltd (Q2 FY26)
Ongoing construction and CAPEX of about INR 25-30 crores for capacity expansion at Khopoli and Nagpur hospitals. Key concall takeaways from Vaidya Sane's Q2…
- Earkart (Q2 FY26)
Earkart has already secured government orders worth approximately ₹9 crores in the current fiscal year (Page 8, 7th excerpt). Key concall takeaways from…
- Prevest Denpro (Q2 FY26)
100 crores in revenue within three years. Key concall takeaways from Prevest Denpro Ltd's Q2 FY26 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were QMS Medical Allied Services Ltd Q2 FY26 results?
Product side growth expected around 10% to 12% annually, aligned with pharma industry growth (Page 12). Product segment expected to grow at 10-12% annually, aligned with pharma industry growth.
What is QMS Medical Allied Services Ltd share price analysis?
QMS Medical Allied Services Ltd currently shows a neutral. The stock trades at a P/E of 21.4 with a market cap of ₹216 Cr. Investors should review the full earnings analysis for detailed insights.
Is QMS Medical Allied Services Ltd planning capital expenditure?
The company is investing heavily in infrastructure and people to support growth and improve margins; these investments are expected to show results from next year onwards.
Keep QMS Medical Allied Services Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.